Differential response patterns to MAO inhibitors and tricyclics.
The concept of atypical depression is reviewed and data comparing the clinical effects of monoamine oxidase inhibitors and tricyclic antidepressants are presented. Monoamine oxidase inhibitors are indicated for treatment of syndromes of panic and generalized anxiety with or without supervening atypical depression. The two classes of drugs have contrasting effects on adrenergic metabolism which may be related to the superior antianxiety and antipanic effects of monoamine oxidase inhibitors.
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000378:metabolism / Q000523:psychology; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D004837:Epinephrine / Q000378:metabolism; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009638:Norepinephrine / Q000378:metabolism; D010043:Outcome and Process Assessment, Health Care; D010200:Panic / Q000187:drug effects; D010624:Phenelzine / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D011569:Psychiatric Status Rating Scales
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D008734:Methoxyhydroxyphenylglycol; D008995:Monoamine Oxidase; D010624:Phenelzine; D007099:Imipramine; D009638:Norepinephrine; D004837:Epinephrine